Status:
NOT_YET_RECRUITING
SafeBoosC-IIIv - Does Cerebral Oximetry Monitoring Affect Renal Outcomes
Lead Sponsor:
St. John's Research Institute
Collaborating Sponsors:
Rigshospitalet, Denmark
Conditions:
Acute Renal Failure
Neonatal Morbidity
Eligibility:
All Genders
1-28 years
Phase:
NA
Brief Summary
Cerebral oximetry monitoring allows clinicians to optimize blood flow to the brain and oxygenation using the SafeBoosC treatment guideline. The guideline's interventions aims to stabilize blood pressu...
Eligibility Criteria
Inclusion
- \> 28 weeks of gestation Invasively ventilated
Exclusion
- major anomalies
Key Trial Info
Start Date :
July 31 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 15 2027
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT06926946
Start Date
July 31 2025
End Date
September 15 2027
Last Update
July 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. jOhn's Medical college & Hospital
Bengaluru, Karnataka, India, 560034